The histone H3.3K36M mutation reprograms the epigenome of chondroblastomas
Author(s) -
Fang Dong,
Haiyun Gan,
JeongHeon Lee,
Jing Han,
Zhiquan Wang,
Scott M. Riester,
Long Jin,
Jianji Chen,
Hui Zhou,
Jinglong Wang,
Honglian Zhang,
Na Yang,
Elizabeth W. Bradley,
Thai H. Ho,
Brian P. Rubin,
Julia A. Bridge,
Stephen N. Thibodeau,
Tamás Ördög,
Yue Chen,
André J. van Wijnen,
André M. Oliveira,
Rui-Ming Xu,
Jennifer J. Westendorf,
Zhiguo Zhang
Publication year - 2016
Publication title -
science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 12.556
H-Index - 1186
eISSN - 1095-9203
pISSN - 0036-8075
DOI - 10.1126/science.aae0065
Subject(s) - epigenome , histone , chromatin , biology , histone h3 , histone methylation , histone methyltransferase , epigenomics , histone code , genetics , microbiology and biotechnology , dna methylation , gene , nucleosome , gene expression
More than 90% of chondroblastomas contain a heterozygous mutation replacing lysine-36 with methionine-36 (K36M) in the histone H3 variant H3.3. Here we show that H3K36 methylation is reduced globally in human chondroblastomas and in chondrocytes harboring the same genetic mutation, due to inhibition of at least two H3K36 methyltransferases, MMSET and SETD2, by the H3.3K36M mutant proteins. Genes with altered expression as well as H3K36 di- and trimethylation in H3.3K36M cells are enriched in cancer pathways. In addition, H3.3K36M chondrocytes exhibit several hallmarks of cancer cells, including increased ability to form colonies, resistance to apoptosis, and defects in differentiation. Thus, H3.3K36M proteins reprogram the H3K36 methylation landscape and contribute to tumorigenesis, in part through altering the expression of cancer-associated genes.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom